![Romulus Brazzell](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Romulus Brazzell
Directeur Technique/Scientifique/R&D chez
KALA BIO, INC.
Fortune : 436 $ au 30/06/2026
Profil
Romulus Kim Brazzell is currently Director at Mimetogen Pharmaceuticals, Inc. since 2024 and Chief Medical Officer, Head-Research & Development at Kala Bio, Inc. since 2021.
Former positions include Associate Director-Research & Development at Alcon Laboratories, Inc. from 1990 to 1991; Executive VP-Medical & Scientific Affairs at Inspire Pharmaceuticals, Inc. from 2010 to 2011; Senior Vice President-US Research & Development at Novartis Ophthalmics, Inc. from 2000 to 2004; Chief Medical Officer at Mimetogen Pharmaceuticals, Inc. from 2012 to 2015; Vice President-Research & Development at Ciba Vision Ophthalmics Co. from 1996 to 2000; and Principal at Acuity Advisors LLC from 2014 to 2018.
Education includes undergraduate and doctorate degrees from the University of Kentucky.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 29/12/2025 | 252 ( 0 % ) | 436 $ | 30/06/2026 |
Postes actifs de Romulus Brazzell
| Sociétés | Poste | Début |
|---|---|---|
| KALA BIO, INC. | Directeur Technique/Scientifique/R&D | 01/02/2013 |
Mimetogen Pharmaceuticals, Inc.
 Mimetogen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops peptidomimetic small molecule drugs against glaucoma and cancer | Directeur/Membre du Conseil | 01/01/2024 |
Anciens postes connus de Romulus Brazzell
| Sociétés | Poste | Fin |
|---|---|---|
Acuity Advisors LLC
 Acuity Advisors LLC Investment ManagersFinance Provides investment advice | Corporate Officer/Principal | 01/07/2018 |
Mimetogen Pharmaceuticals, Inc.
Mimetogen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops peptidomimetic small molecule drugs against glaucoma and cancer | Directeur Technique/Scientifique/R&D | 01/12/2015 |
Inspire Pharmaceuticals, Inc.
 Inspire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes ophthalmic products | Directeur Technique/Scientifique/R&D | 01/01/2011 |
Novartis Ophthalmics, Inc.
 Novartis Ophthalmics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals, eye care and generic drugs | Directeur Technique/Scientifique/R&D | 01/01/2004 |
Ciba Vision Ophthalmics Co. | Directeur Technique/Scientifique/R&D | 01/01/2000 |
Formation de Romulus Brazzell
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
57
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Inspire Pharmaceuticals, Inc.
Inspire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes ophthalmic products | Health Technology |
Kala Bio, Inc.
 Kala Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company developing mesenchymal stem cell secretive (MSC-S) therapies | Health Technology |
Alcon Laboratories, Inc.
 Alcon Laboratories, Inc. Medical SpecialtiesHealth Technology Operates as an eye care device company | Health Technology |
University of Kentucky
 University of Kentucky Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis Ophthalmics, Inc.
Novartis Ophthalmics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals, eye care and generic drugs | Health Technology |
Mimetogen Pharmaceuticals, Inc.
Mimetogen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops peptidomimetic small molecule drugs against glaucoma and cancer | Health Technology |
Ciba Vision Ophthalmics Co. | |
Acuity Advisors LLC
Acuity Advisors LLC Investment ManagersFinance Provides investment advice | Finance |
